COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Department of Pharmacology Seminar Series > Exploiting nuclear envelope dysfunction in progeria to identify new therapeutic targets for ageing
Exploiting nuclear envelope dysfunction in progeria to identify new therapeutic targets for ageingAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact comms. Biography Dr Delphine Larrieu has been a Wellcome Trust Sir Henry Dale fellow and a Group Leader at the University of Cambridge since 2017. She initially set up her lab at the CIMR where she stayed for 5 years, and she was then appointed Assistant Professor in the Department of Pharmacology, where she relocated in October 2022. After working on tumour suppressor genes during her PhD at the University Grenoble Alpes (France), she developed a strong interest in the mechanisms linking nuclear envelope dysfunction with ageing and premature ageing syndromes (progerias) during her postdoctoral training in Steve Jackson’s lab at the Gurdon Institute – Cambridge. Her work has focused on the identification of new markers and modulators of nuclear envelope integrity, to unravel the mechanisms underlying nuclear envelope dysfunction, improve our understanding of premature and physiological ageing and contribute to the development of novel therapies. She has developed pioneering approaches based on the principle of synthetic rescue and relying on cutting-edge genetic screening approaches, and identified novel, unexpected targets and cellular pathways that can reverse several age-related nuclear envelope phenotypes. Her current efforts are focused on characterising and expanding the number of targets that can be exploited therapeutically to extend health and lifespan in progeria syndromes as well as in ageing. Dr Larrieu is a co-founder of Adrestia Therapeutics – recently acquired by Insmed – a synthetic rescue company whose aim of restoring cellular balance in genetic diseases was directly inspired by her work. Zoom link: https://zoom.us/j/94068850972?pwd=YmJoRTQ2NUZDRFNHWXd2R0FDc0hUUT09 Meeting ID: 940 6885 0972 Passcode: uY27KQv8cu This talk is part of the Department of Pharmacology Seminar Series series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsCambridge Review of International Affairs Cambridge International Development Conference WP Page Builder: The Ultimate Visual Editor for WordPress SitesOther talksThe strange world of AdS2 integrability CGHR Student Group 2023-24: Introductory Meeting UK Graduate Modelling Camp – Mentor and Mentee perspectives Goldman Sachs - Quantitative Finance and AI Averaging to Higher Depth Mock Modular Forms The quiet AI revolution in weather forecasting |